Introduction
============

Diabetes is a common condition in the long-term care (LTC) setting, where approximately 25% of LTC facility residents in the US are affected.[@b1-cia-9-1815] Diabetes management in this setting is complicated because, compared with individuals without diabetes, diabetes is often associated with increased rates of premature mortality, functional disability, cognitive dysfunction, and comorbidities (eg, hypertension, stroke, coronary heart disease, depression, dementia) in elderly patients.[@b2-cia-9-1815],[@b3-cia-9-1815] Factors such as renal insufficiency, coexisting illnesses, polypharmacy, irregular meal patterns, and cognitive and functional impairment can lead to an increased risk of hypoglycemia in the elderly;[@b4-cia-9-1815] therefore, optimizing the treatment of diabetes is a vital component of the care required in LTC facilities.[@b1-cia-9-1815],[@b5-cia-9-1815]

When considering diabetes management in the LTC setting, long-acting insulin analogs are a favorable treatment option because of their "peakless" profile, which reduces the risk of hypoglycemia compared with intermediate-acting insulins, such as neutral protamine Hagedorn (NPH) insulin.[@b6-cia-9-1815] In patients with type 2 diabetes mellitus (T2DM), adding a long-acting insulin analog to an oral antidiabetic drug (OAD) is a simple, safe, and effective strategy for introducing insulin therapy when OADs are no longer adequate to control hyperglycemia.[@b1-cia-9-1815]

Despite recommendations on the use of insulin analogs in elderly patients with T2DM, the use of regular insulin and sliding scale insulin (SSI) regimens continue to be commonplace.[@b7-cia-9-1815],[@b8-cia-9-1815] To the authors' knowledge, no investigation has been undertaken of basal insulin use and its associated outcomes among elderly nursing home residents with T2DM.

The objective of this retrospective study was to determine practice patterns and clinical outcomes associated with the use of basal insulin regimens in elderly T2DM patients residing in US LTC facilities.

Methods
=======

Study design
------------

This was a cross-sectional retrospective study conducted in elderly T2DM patients residing in US LTC facilities. The objective was to describe practice patterns and clinical outcomes associated with three insulin regimens: the long-acting insulin analog glargine (GLA); the long-acting insulin analog detemir (DET); and the intermediate-acting insulin NPH. Data were extracted from medical charts and merged with preexisting data from the Minimum Data Set (MDS). The MDS is a standardized and comprehensive assessment instrument that describes medical diagnoses, chronic health conditions, medication use and other interventions, cognitive function, psychosocial wellbeing, functional status, and other aspects of the health of patients residing in LTC facilities. Chart data provided information on patient characteristics, dosing regimens, and glycemic profiles as well as other pharmacological treatments and clinical outcomes not captured in the MDS. Data were collected from September 2010 through to September 2011. As the study used preexisting, de-identified data, it was exempt from approval by an Institutional Review Board committee.

Patients
--------

Patients were eligible for inclusion in the study if they: had been newly admitted to the LTC facility after January 1, 2009 and resident in the LTC facility for ≥3 months; had at least one full MDS assessment; had at least two records of insulin dispensing (at least one of which was GLA, DET, or NPH); and had a diagnosis of diabetes (as recorded on the MDS form). Exclusion criteria included a diagnosis of type 1 diabetes, pump-administered insulin at any point after LTC admission, and a comatose state or receiving hospice care on or at any point after the date of LTC admission.

Study measures
--------------

To determine practice patterns and clinical outcomes associated with insulin use, the following data were collected: patient demographics and clinical characteristics (including age, sex, race, body mass index, activities of daily living/assistance, comorbidities, and use of other non-insulin antidiabetic agents), information on co-administration of prandial/bolus insulins or SSI, and information on dosing frequency and route of administration. Patients who changed insulin regimens during the course of the study were categorized as having received multiple regimens.

The primary clinical outcome of interest was glycemic control as measured by the mean levels across all observed records for glycated hemoglobin (HbA~1c~), fasting blood glucose (FBG) levels during all available follow-up periods available under the Medication Administration Record Sheet, and preprandial blood glucose (PBG) levels. In addition, the percentage of patients with at least one measurement of FBG ≤100 mg/dL, PBG ≤125 mg/dL, and HbA~1c~ ≤7.0% or HbA~1c~ \<8.5% was obtained. HbA~1c~ data were obtained from medical records and FBG and PBG levels were obtained from the Medication Administration Record Sheet. Although recent guidelines have recommended an HbA~1c~ goal of ≤7.5% for otherwise healthy, elderly diabetes patients, the HbA~1c~ goal of ≤7.0% was ubiquitously accepted at the time the study was conducted. The HbA~1c~\<8.5% goal has been recommended for those elderly patients with complex needs, and cognitive and functional impairments who are likely to make up a large proportion of the LTC population.[@b3-cia-9-1815]

Data on the occurrence of specific adverse events associated with the insulin regimens (GLA, DET, and NPH) were collected, and included the incidence of hypoglycemia-related events (overall incidence and incidence of moderate events, defined as events with a confirmed blood glucose level of \<50 mg/dL) and other adverse events, ie, falls, ketoacidosis, hospitalizations, infections, and emergency room visits.

Statistical analyses
--------------------

Data were analyzed using mean values, medians, ranges, and standard deviations (SDs) of continuous variables, and frequency distributions for categorical variables. Outcomes were compared between treatment groups. *P*-values were derived from Mann--Whitney *U*-tests for dichotomous variables, and from Student's *t*-tests for continuous variables.

Results
=======

Patient demographics and baseline characteristics
-------------------------------------------------

A total of 2,096 elderly, insulin-treated patients with T2DM were identified from 117 facilities. Of these, 59.5% of patients (N=1,247) had at least one record of dispensation of basal insulin: 933 (74.8%) were treated with GLA, 199 (16.0%) with DET, and 115 (9.2%) with NPH during the observation period, and were included in the analysis.

The baseline demographic and clinical characteristics of the 1,247 patients, stratified by the type of insulin they received, are summarized in [Tables 1](#t1-cia-9-1815){ref-type="table"} and [2](#t2-cia-9-1815){ref-type="table"}. Baseline demographics were similar across the treatment groups. The mean age of patients was 73.6 years (SD ±12.0), and most patients were women (60.3%) and white (52.5%) ([Table 1](#t1-cia-9-1815){ref-type="table"}). Assessment of assisted daily living status indicated that 12.0% of patients were able to live independently with regards to their daily activities, 14.3% required supervision but without assistance, 34.0% required limited assistance, and 21.6% extensive assistance. Mean follow-up duration was 49.0 days (SD ±29.4) (range 6--424 days).

The most common comorbidities reported in this patient population were Alzheimer's disease/dementia (50.8%) and stroke (24.3%) ([Table 2](#t2-cia-9-1815){ref-type="table"}). Almost all patients (95.8%) used medications to treat chronic conditions, most commonly with antihypertensive drugs (81.4%), anticoagulant/antiplatelet drugs (58.5%), or antidepressant drugs (56.9%). Concomitant OADs -- most commonly metformin (18.7%) or sulfonylureas (12.8%) -- were used by 30.8% of patients. Although patients in the NPH insulin group tended to have less depression and lower associated concomitant medication use compared with patients in the GLA or DET groups, there were no significant between-group differences.

Insulin treatment regimen, administration, and dosage
-----------------------------------------------------

The most commonly-used insulin treatment regimen was basal insulin co-administered with SSI, followed by basal insulin only ([Figure 1A](#f1-cia-9-1815){ref-type="fig"}). Approximately 17% of patients received an additional bolus insulin, either alone or with supplemental SSI.

Insulin pen use was generally low; 14.6% of patients received insulin via an injectable pen device ([Figure 1B](#f1-cia-9-1815){ref-type="fig"}). A significantly lower proportion of patients in the GLA group (111 of 993 \[11.9%\]) compared with the DET group (68 of 199 \[34.2%\]) received their analog insulin via a pen (*P*\<0.0001). Very few patients (2 of 115 \[1.7%\]) received NPH via a pen.

There were no significant differences between the groups with regards to mean daily insulin dose: 26.8 units/day (SD ±19.1) in the GLA group; 27.7 units/day (SD ±22.0) in the DET group; and 26.8 units/day (SD ±19.1) in the NPH group. However, significantly fewer patients in the GLA group required twice-daily insulin injections (5.6%) compared with either the DET (22.1%; *P*\<0.0001) or NPH insulin (64.3%; *P*\<0.0001) groups.

Glycemic control
----------------

A total of 485 patients (38.9%) had at least one HbA~1c~ measurement recorded in their medical chart; at least one HbA~1c~ measurement was recorded for 40.0% of patients in the GLA group, 38.2% of patients in the DET group, and 31.3% of patients in the NPH group. Among those with at least HbA~1c~ measurement, mean HbA~1c~ in the GLA group was 7.31% (SD ±1.31), which was significantly lower than that in the DET group (7.72% \[SD ±1.41\]; *P*=0.0184) and numerically higher than the NPH group (6.93% \[SD ±1.25\]; *P*=0.1099) ([Figure 2A](#f2-cia-9-1815){ref-type="fig"}). Similar percentages of patients in all three treatment groups had at least one measurement of HbA~1c~ of ≤7.0% (ie, 47.5% of patients in the GLA group, 39.5% in the DET group, and 61.1% in the NPH group: GLA versus DET *P*=0.2034 and GLA versus NPH *P*=0.1147) ([Figure 2B](#f2-cia-9-1815){ref-type="fig"}). Despite numerical differences, there were no significant differences in the proportions of patients with at least one measurement of HbA~1c~ \<8.5% during the observation period for the three treatment groups (ie, 83.7% of patients in the GLA group, 79.0% of patients in the DET group, and 86.1% of patients in the NPH group: GLA versus DET *P*=0.3219 and GLA versus NPH *P*=0.7010).

Similar percentages of patients in all three treatment groups had at least one measurement of FBG ≤100 mg/dL (ie, 51.7% of patients in the GLA group, 46.1% of patients in the DET group, and 50.9% of patients in the NPH group: GLA versus DET *P*=0.1681 and GLA versus NPH *P*=0.8732) ([Figure 2B](#f2-cia-9-1815){ref-type="fig"}). There were no significant differences between GLA, DET, or NPH with regards to mean FBG levels (151.8 mg/dL, 154.3 mg/dL, and 145.9 mg/dL, respectively) ([Figure 2C](#f2-cia-9-1815){ref-type="fig"}). Similar percentages of patients in each group had at least one measurement of PBG ≤125 mg/dL ([Figure 2B](#f2-cia-9-1815){ref-type="fig"}).

Adverse events
--------------

The incidences of patients experiencing at least one adverse event while receiving the three insulin regimens are summarized in [Table 3](#t3-cia-9-1815){ref-type="table"}. Overall, the most common adverse event was infections (15.9%). A significantly lower proportion of patients in the GLA group (9.3%) than in the DET group (16.6%) had a urinary infection (*P*=0.0025); there were no significant differences between the three treatment groups in the incidence of other adverse events. Only a small proportion of patients had ketoacidosis during the observation period (overall incidence rate of 0.33 events per 100 person-months).

Of the 1,247 patients included in the analysis, 214 (17.2%) experienced at least one hypoglycemic event during follow-up, and 47 patients (3.8%) had at least one moderate hypoglycemic event -- there were no significant between-group differences ([Table 3](#t3-cia-9-1815){ref-type="table"}). The incidence rate of hypoglycemic events per 100 person-months was 24.3 in the GLA group, 18.6 in the DET group, and 15.7 in the NPH group. The incidence rates of moderate hypoglycemic events were 3.2 per 100 person-months in the GLA group, 4.8 per 100 person-months in the DET group, and 1.8 per 100 person-months in the NPH group.

Discussion
==========

Data from several studies suggest that a significant proportion of elderly LTC facility residents receive suboptimal diabetes care,[@b1-cia-9-1815] despite the identification of numerous opportunities for improving care quality among nursing home residents with diabetes.[@b9-cia-9-1815] For example, the development of treatment algorithms, together with the implementation of quality improvement tools that follow appropriate process and outcome indicators have been proposed as a means of improving the management of diabetes in this setting.[@b9-cia-9-1815] Surprisingly little research has been carried out, however, to understand the pattern of insulin use in this elderly LTC population, given that the addition of a basal insulin to OADs is a recognized strategy for introducing insulin therapy.[@b1-cia-9-1815],[@b10-cia-9-1815] This study, one of the first of its kind, described basal insulin use and its associated outcomes among elderly LTC facility residents with T2DM.

One of the main treatment patterns identified in this study indicated that \<60% of patients had received basal insulin; the remainder had been exclusively treated with SSI and more than half of these patients had used basal insulin in conjunction with SSI. This high prevalence of SSI is a cause for concern, given that its use is inconsistent with current recommendations[@b5-cia-9-1815],[@b8-cia-9-1815],[@b11-cia-9-1815] and is associated with limited therapeutic success[@b7-cia-9-1815] and high burden of unnecessary finger sticks.[@b11-cia-9-1815] The continued use of SSI may be due to clinical inertia and its position as a "medical myth" passed on through generations of health care professionals.[@b7-cia-9-1815] Staff or clinicians may not be aware of the ineffectiveness of SSI.[@b12-cia-9-1815] SSI may also be perpetuated as it provides the opportunity to administer various doses of insulin in a reactive manner for a wide range of blood glucose levels without having to call the practitioner or analyze glucose patterns to make a logical change in the insulin regimen. The change in medical culture required to move away from SSI is not simple and requires the involvement of the multidisciplinary team;[@b13-cia-9-1815] perhaps greater involvement from pharmacy staff, who can help promote the individualization of treatment, may aid the shift away from SSI.[@b12-cia-9-1815]

Concomitant OADs were used by 30.8% of patients, most commonly metformin (18.7%) or sulfonylureas (12.8%). Among patients who had received basal insulin, one in four received basal only with a majority requiring additional prandial insulin (basal insulin plus SSI comprised the predominant insulin regimen used).

Of the different basal insulins investigated in this study, GLA had been used by three in four patients, a finding in line with previous studies.[@b14-cia-9-1815] Another pattern identified in this study was that NPH was mostly used twice daily, and patients receiving DET were significantly more likely to receive insulin twice daily than those receiving GLA. Injectable pen use was low despite the availability, for all three insulins, of insulin pens. A possible explanation for this is the relatively high acquisition cost of insulin pens and the high use of SSI, which is married to the syringe vial paradigm. Insulin pens are easier to use and offer improved treatment adherence and persistence, and a lower incidence of hypoglycemia compared with vial and syringe administration in real-world ambulatory settings.[@b15-cia-9-1815] Diabetes management in elderly LTC facility residents might, therefore, be improved by switching to insulin pens.

With regard to glycemic control, differences were found between the three treatment groups. A significantly lower HbA~1c~ level was reported for GLA-treated patients than for those treated with DET. This finding is consistent with a previous real-world study that reported better glycemic control in patients initiating insulin therapy with GLA, than those initiating with DET.[@b16-cia-9-1815] However, it should be noted that tight HbA~1c~ control may not be appropriate for all patients and assessment of comparative effectiveness was not the goal of this study.

An HbA~1c~ target level of \<7.0% is a reasonable goal for most patients and provides the potential benefit of reducing microvascular and macrovascular disease. However, this goal carries an increased risk of hypoglycemia that must be weighed against its potential benefits in elderly patients with T2DM.[@b4-cia-9-1815] A low percentage of patients achieved at least one measurement of HbA~1c~ ≤7.0% in the current study, supporting the suggestion that achievement of this target HbA~1c~ level is not necessarily an appropriate goal for elderly T2DM patients residing in LTC facilities.[@b3-cia-9-1815],[@b17-cia-9-1815] Due to the unique presentations and challenges of diabetes and its chronic complications in the elderly, treatment goals in this population should be tailored to the individual patient.[@b2-cia-9-1815],[@b18-cia-9-1815] The majority of patients in all three treatment groups reached the comparatively less stringent HbA~1c~ target of \<8.5%, which may be a more appropriate HbA~1c~ level for functionally and cognitively impaired elderly patients in an LTC setting.

With regards to safety and tolerability, the prevalence of hypoglycemia did not significantly differ between treatment groups. The proportion of LTC residents with at least one hypoglycemic event was approximately 17%, which is in accordance with previous studies reporting hypoglycemia prevalence rates in elderly patients with diabetes (range 15%--27%).[@b19-cia-9-1815],[@b20-cia-9-1815] There were no significant differences between the three treatment groups in the incidence of most adverse events, although a significantly lower rate of urinary tract infections was detected in the GLA group compared with the DET group.

One of the strengths of this study was that chart data were used to provide information on patient characteristics, dosing regimens, and glycemic profiles, as well as other pharmacological treatments and clinical outcomes not captured in the MDS. Furthermore, this was a large-scale study that included \>1,200 elderly LTC facility residents with T2DM receiving insulin therapy. Nevertheless, data collection relied on convenience sampling so these findings cannot be generalized to the overall US elderly LTC facility population. Other limitations were that the study's cross-sectional design did not permit assessment of the comparative effectiveness of the three insulin treatments; the data collection was retrospective and relied on medical chart abstraction and the MDS (including that for hypoglycemia events) and therefore was unable to capture information such as patient education, dietary control, and lifestyle, which are important for understanding comprehensive management of elderly diabetes patients; and the information collected could also have been subject to measurement errors. There could also be an element of interindividual variability of OAD treatment due to genetic mechanisms,[@b21-cia-9-1815] which may influence these results. Furthermore, because the timing of the HbA~1c~ measurement could not be determined, the relationship between HbA~1c~ and insulin treatment cannot be inferred and the levels might have been related to other treatments. The findings of this study should, therefore, be interpreted conservatively and require confirmation in randomized trials.

Conclusion
==========

The data from this retrospective study conducted in elderly T2DM patients reveal that, among US LTC facility residents, basal insulin may still be underutilized and that when used it is often in conjunction with SSI. Vial and syringe use was still the dominant mode of administration despite the potential benefits of insulin pens. Pragmatic randomized trials should be conducted to investigate if specific basal insulins have a therapeutic advantage in this patient group.
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![Commonly used treatment regimens.\
**Note:** (**A**) Insulin treatment regimen. (**B**) Insulin type and administration.\
**Abbreviations:** DET, insulin detemir; GLA, insulin glargine; NPH, neutral protamine Hagedorn insulin; SSI, sliding scale insulin.](cia-9-1815Fig1){#f1-cia-9-1815}

![Glycemic control among patients receiving basal insulin.\
**Notes:** (**A**) Mean HbA~1c~ levels by treatment group. (**B**) Percentage of patients with at least one measurement at or below designated levels for HbA~1c~ (≤7.0%), FBG (≤100 mg/dL), and PBG (≤125 mg/dL). (**C**) Mean FBG levels by treatment group. \**P*=0.0184 versus GLA.\
**Abbreviations:** DET, insulin detemir; FBG, fasting blood glucose; GLA, insulin glargine; HbA~1c~, glycated hemoglobin; NPH, neutral protamine Hagedorn insulin; PBG, preprandial blood glucose.](cia-9-1815Fig2){#f2-cia-9-1815}

###### 

Patient baseline characteristics

  --------------------------------------------------------------------------------------------------------
                                                 All patients\   GLA\          DET\          NPH\
                                                 (N=1,247)       (n=933)       (n=199)       (n=115)
  ---------------------------------------------- --------------- ------------- ------------- -------------
  Sex, n (%)                                                                                 

   Male                                          495 (39.7%)     371 (39.8%)   80 (40.2%)    44 (38.3%)

   Female                                        752 (60.3%)     562 (60.2%)   119 (59.8%)   71 (61.7%)

  Age, (years)                                                                               

   \<65                                          299 (24.0%)     229 (24.5%)   44 (22.1%)    26 (22.6%)

   65--74                                        320 (25.7%)     248 (26.6%)   51 (25.6%)    21 (18.3%)

   75--84                                        378 (30.3%)     283 (30.3%)   58 (29.2%)    37 (32.2%)

   ≥85                                           250 (20.1%)     173 (18.5%)   46 (23.1%)    31 (27.0%)

   Mean (SD)                                     73.6 (12.0)     73.2 (12.0)   74.2 (12.0)   75.4 (12.4)

   Median (range)                                75 (28--92)     74 (28--92)   75 (34--92)   78 (43--92)

  Race, n (%)                                                                                

   White                                         654 (52.5%)     486 (52.1%)   107 (53.8%)   61 (53.0%)

   Black                                         410 (32.9%)     305 (32.7%)   67 (33.7%)    38 (33.0%)

   Hispanic                                      149 (12.0%)     113 (12.1%)   20 (10.1%)    16 (13.9%)

   Other                                         34 (2.7%)       29 (3.1%)     5 (2.5%)      0

  Height (m), mean (SD)                          1.7 (0.1)       1.7 (0.1)     1.7 (0.1)     1.7 (0.1)

  Weight (kg), mean (SD)                         84.8 (27.3)     85.1 (27.2)   85.5 (29.7)   81.5 (24.2)

  Body mass index (kg/m^2^), mean (SD)           30.8 (10.0)     30.8 (9.9)    31.6 (11.4)   29.5 (8.6)

  Activities of daily living assistance, n (%)                                               

   Independent                                   149 (12.0%)     115 (12.3%)   21 (10.6%)    13 (11.3%)

   Supervision without assistance                178 (14.3%)     136 (14.6%)   27 (13.6%)    15 (13.0%)

   Limited assistance                            424 (34.0%)     323 (34.6%)   64 (32.2%)    37 (32.2%)

   Extensive assistance                          269 (21.6%)     193 (20.7%)   45 (22.6%)    31 (27.0%)

   Total dependence                              227 (18.2%)     166 (17.8%)   42 (21.1%)    19 (16.5%)

  Follow-up duration (days), mean (SD)           49.0 (29.4)     49.9 (30.4)   47.7 (29.6)   44.1 (18.9)
  --------------------------------------------------------------------------------------------------------

**Abbreviations:** DET, insulin detemir; GLA, insulin glargine; NPH, neutral protamine Hagedorn insulin; SD, standard deviation.

###### 

Baseline comorbidities, chronic-use medications, and concomitant antidiabetic agents used by study patients

  ----------------------------------------------------------------------------------------------
                                        All patients\   GLA\          DET\          NPH\
                                        (N=1,247)       (n=933)       (n=199)       (n=115)
  ------------------------------------- --------------- ------------- ------------- ------------
  Current comorbidities                                                             

   Depression                           415 (33.3%)     318 (34.1%)   63 (31.7%)    34 (29.6%)

   Alzheimer's disease/dementia         72 (5.8%)       57 (6.1%)     9 (4.5%)      6 (5.2%)

   Hypertension                         633 (50.8%)     482 (51.7%)   93 (46.7%)    58 (50.4%)

   COPD                                 145 (11.6%)     103 (11.0%)   32 (16.1%)    10 (8.7%)

   Cancer                               22 (1.8%)       17 (1.8%)     4 (2.0%)      1 (0.9%)

   Stroke                               303 (24.3%)     247 (26.5%)   32 (16.1%)    24 (20.9%)

  Other concomitant medications                                                     

   Antihypertensive drugs               1015 (81.4%)    761 (81.6%)   164 (82.4%)   90 (78.3%)

   Antihyperlipidemic drugs             599 (48.0%)     447 (47.9%)   97 (48.7%)    55 (47.8%)

   Antidepressant drugs                 710 (56.9%)     553 (59.3%)   106 (53.3%)   51 (44.4%)

   Anticoagulant/antiplatelet drugs     729 (58.5%)     556 (59.6%)   115 (57.8%)   58 (50.4%)

   Respiratory agents (anti-COPD)       286 (22.9%)     214 (22.9%)   45 (22.6%)    27 (23.5%)

  Concomitant oral antidiabetes drugs                                               

   Metformin                            233 (18.7%)     180 (19.3%)   31 (15.6%)    22 (19.1%)

   GLP-1 receptor analogs               1 (0.1%)        0             1 (0.5%)      0

   DPP-4 inhibitors                     34 (2.7%)       27 (2.9%)     6 (3.0%)      1 (0.9%)

   Thiazolidinediones                   41 (3.3%)       32 (3.4%)     5 (2.5%)      4 (3.5%)

   Sulfonylureas                        159 (12.8%)     126 (13.5%)   23 (11.6%)    10 (8.7%)

   Meglitinides                         10 (0.8%)       8 (0.9%)      2 (1.0%)      0
  ----------------------------------------------------------------------------------------------

**Abbreviations:** COPD, chronic obstructive pulmonary disease; DET, insulin detemir; DPP-4, dipeptidyl peptidase-4; GLA, insulin glargine; GLP-1, glucagon-like peptide-1; NPH, neutral protamine Hagedorn insulin.

###### 

Incidence of adverse events

  --------------------------------------------------------------------------------------------------------------------------
  Adverse event           All patients\   GLA\          DET\                                                    NPH\
                          (N=1,247)       (n=933)       (n=199)                                                 (n=115)
  ----------------------- --------------- ------------- ------------------------------------------------------- ------------
  Hypoglycemia                                                                                                  

   Any                    214 (17.2%)     170 (18.2%)   31 (15.6%)                                              13 (11.3%)

   Moderate               47 (3.8%)       33 (3.5%)     11 (5.5%)                                               3 (2.6%)

  Infection                                                                                                     

   Any                    198 (15.9%)     145 (15.5%)   41 (20.6%)                                              12 (10.4%)

   Urinary                128 (10.3%)     87 (9.3%)     33 (16.6%)[\*](#tfn3-cia-9-1815){ref-type="table-fn"}   8 (7.0%)

   Respiratory            41 (3.3%)       32 (3.4%)     5 (2.5%)                                                4 (3.5%)

   Wound                  24 (1.9%)       16 (1.7%)     8 (4.0%)                                                0

   Other                  40 (3.2%)       33 (3.5%)     4 (2.0%)                                                3 (2.6%)

  Falls                   51 (4.1%)       39 (4.2%)     11 (5.5%)                                               1 (0.9%)

  Emergency room visits   26 (2.1%)       21 (2.3%)     2 (1.0%)                                                3 (2.6%)

  Ketoacidosis            6 (0.5%)        3 (0.3%)      3 (1.5%)                                                0

  Hospitalizations        4 (0.3%)        3 (0.3%)      1 (0.5%)                                                0
  --------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*=0.0025 versus GLA.

**Abbreviations:** DET, insulin detemir; GLA, insulin glargine; NPH, neutral protamine Hagedorn insulin.
